CD45 为细胞因子癌症免疫疗法穿针引线

IF 27.7 1区医学 Q1 IMMUNOLOGY

Nature Immunology Pub Date : 2024-09-09 DOI:10.1038/s41590-024-01956-0

Nils Wellhausen, Saar Gill

引用次数: 0

摘要

免疫细胞因子是基于细胞因子的融合蛋白，具有治疗潜力。新型 CD45 靶向免疫细胞因子可通过延长在 T 细胞和树突状细胞上的滞留时间，重新规划全身抗肿瘤免疫，同时通过瘤内给药将全身毒性降至最低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

CD45 threads the needle of cytokine cancer immunotherapy

查看原文本刊更多论文

CD45 threads the needle of cytokine cancer immunotherapy

Immunocytokines are cytokine-based fusion proteins with therapeutic potential. New CD45-targeted immunocytokines can reprogram systemic anti-tumor immunity by prolonged retention on T cells and dendritic cells while minimizing systemic toxicities through intratumoral delivery.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Immunology 医学-免疫学

CiteScore

40.00

自引率

2.30%

发文量

248

审稿时长

4-8 weeks

期刊介绍： Nature Immunology is a monthly journal that publishes the highest quality research in all areas of immunology. The editorial decisions are made by a team of full-time professional editors. The journal prioritizes work that provides translational and/or fundamental insight into the workings of the immune system. It covers a wide range of topics including innate immunity and inflammation, development, immune receptors, signaling and apoptosis, antigen presentation, gene regulation and recombination, cellular and systemic immunity, vaccines, immune tolerance, autoimmunity, tumor immunology, and microbial immunopathology. In addition to publishing significant original research, Nature Immunology also includes comments, News and Views, research highlights, matters arising from readers, and reviews of the literature. The journal serves as a major conduit of top-quality information for the immunology community.